Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 10/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.61 |
| ▸ | TUBB | P07437 | 5/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.61 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.61 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.61 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.61 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.61 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.61 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.61 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.61 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.61 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.61 |
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593827 | 1.00 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17145723 | 0.94 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10030791 | 0.91 | TUBB1 (0.51) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13456507 | 0.90 | APP (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12774239 | 0.90 | TUBB1 (0.63) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13223387 | 0.89 | TUBB1 (0.49) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13223338 | 0.87 | TUBB1 (0.47) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14192136 | 0.86 | TUBB1 (0.74) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17145750 | 0.86 | TUBB1 (0.49) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12774233 | 0.85 | TUBB1 (0.50) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45720-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2562154-A1 | Method for preparing combretastatin | SANOFI (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120046492-A1 | Ethoxy Diphenyl Ethane Derivatives, Preparation Processes and Uses Thereof | Zhejiang Wild Wind Pharmaceutical Co., Ltd. (CN) | 2012-02-23 | — | — | US | disclosed |
| EP-2354118-A1 | Process for the preparation of combretastatine | Aventis Pharma S.A. (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7973076-B2 | Anti-tumor composition | AJINOMOTO CO., INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110054035-A1 | Combination Comprising Combretastatin and Anticancer Agents | AVENTIS PHARMA S.A. (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110054035-A1 | Combination Comprising Combretastatin and Anticancer Agents | AVENTIS PHARMA S.A. (FR) | 2011-03-03 | — | — | US | disclosed |
| US-7851443-B2 | Combination comprising combretastatin and anticancer agents | AVENTIS PHARMA SA (FR) | 2010-12-14 | — | — | US | disclosed |
| US-20100069486-A1 | ANTI-TUMOR COMPOSITION | AJINOMOTO CO., INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7655696-B2 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | AJINOMOTO CO., INC. (JP) | 2010-02-02 | — | — | US | disclosed |
| WO-2009118474-A1 | METHOD FOR PREPARING COMBRETASTATIN | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
| US-20090093540-A1 | ANTI-TUMOR COMPOSITION | AJINOMOTO CO., INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090023656-A1 | Combination Comprising Combretastatin and Anticancer Agents | AVENTIS PHARMA S.A. (FR) | 2009-01-22 | — | — | US | disclosed |
| US-20070149476-A1 | Combination Comprising Combretastatin and Anticancer Agents | AVENTIS PHARMA S.A. (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149476-A1 | Combination Comprising Combretastatin and Anticancer Agents | TOP1, TOP2A, TOP2B | TUBB1 110/4885TUBB4A 112/4885TUBB 106/4885 |
| US-20090023656-A1 | Combination Comprising Combretastatin and Anticancer Agents | TEK, FLT4, FLT1 | TUBB1 47/4885TUBB4A 76/4885TUBB 46/4885 |
| US-20100069486-A1 | ANTI-TUMOR COMPOSITION | TP53, VHL, MKI67 | TUBB1 129/4885TUBB4A 194/4885TUBB 195/4885 |
| US-20110054035-A1 | Combination Comprising Combretastatin and Anticancer Agents | TEK, FLT4, FLT1 | TUBB1 47/4885TUBB4A 76/4885TUBB 46/4885 |
| US-20090093540-A1 | ANTI-TUMOR COMPOSITION | TP53, VHL, MKI67 | TUBB1 191/4885TUBB4A 291/4885TUBB 293/4885 |
| US-20120046492-A1 | Ethoxy Diphenyl Ethane Derivatives, Preparation Processes and Uses Thereof | TUBB1, TUBB, TUBB3 | TUBB1 1/4885TUBB4A 6/4885TUBB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.